To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom.
Sant Marti de Provençals Primary Care Centres, Institut Català de la Salut, University Research Institute in Primary Care (IDIAP Jordi Gol), Barcelona, Spain.
Primary Care Metabolic Group, Los Angeles, CA, USA.
Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Show others and affiliations
2021 (English)In: Primary Care Diabetes, ISSN 1751-9918, E-ISSN 1878-0210, Vol. 15, no 1, p. 31-51Article in journal (Refereed) Published
Abstract [en]

Type 2 diabetes and its associated comorbidities are growing more prevalent, and the complexity of optimising glycaemic control is increasing, especially on the frontlines of patient care. In many countries, most patients with type 2 diabetes are managed in a primary care setting. However, primary healthcare professionals face the challenge of the growing plethora of available treatment options for managing hyperglycaemia, leading to difficultly in making treatment decisions and contributing to therapeutic inertia. This position statement offers a simple and patient-centred clinical decision-making model with practical treatment recommendations that can be widely implemented by primary care clinicians worldwide through shared-decision conversations with their patients. It highlights the importance of managing cardiovascular disease and elevated cardiovascular risk in people with type 2 diabetes and aims to provide innovative risk stratification and treatment strategies that connect patients with the most effective care.

Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 15, no 1, p. 31-51
Keywords [en]
Cardiovascular disease, Cardiovascular risk factors, Chronic kidney disease, Elderly, Heart failure, Multimorbidity, Patient-centred care, Primary care, Shared decision making, Therapeutic inertia, Type 2 diabetes
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-83200DOI: 10.1016/j.pcd.2020.05.004ISI: 000604616900010PubMedID: 32532635Scopus ID: 2-s2.0-85086150627OAI: oai:DiVA.org:oru-83200DiVA, id: diva2:1470763
Funder
Novo Nordisk
Note

Funding Agencies:

National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care -East Midlands  

NIHR Leicester Biomedical Research Centre 

Available from: 2020-09-25 Created: 2020-09-25 Last updated: 2021-02-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Jansson, Stefan P. O.

Search in DiVA

By author/editor
Jansson, Stefan P. O.
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Primary Care Diabetes
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 109 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf